We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

MRSA/SA PCR Rapid Test Quickly Diagnoses Methicillin Resistance at Point of Care

By LabMedica International staff writers
Posted on 06 Oct 2022
Print article
Image: Vivalytic test MRSA/SA provides quick diagnosis of methicillin resistance at POC (Photo courtesy of Bosch)
Image: Vivalytic test MRSA/SA provides quick diagnosis of methicillin resistance at POC (Photo courtesy of Bosch)

Methicillin-resistant (MRSA) is a major multi-resistant nosocomial pathogen worldwide with the WHO estimating that the mortality rate of patient infection rates is around 50% higher compared with patients who have been infected by non-resistant Staphylococcus aureus strains. Moreover, the extensive period of hospitalization, morbidity, and the associated medical costs increase significantly with an MRSA infection. The treatment on the front line today looks at increasing empirical antibiotic prescribing and increasing drug-resistant outbreaks. Speed is key here - since the result of diagnostics with culture sampling, which is the current traditional method for MRSA testing is only available after one to three days. Now, a new test for the quick diagnosis of MRSA at the point of the care not only provides rapid RT-PCR results in 53 minutes but differentiates whether the bacterial strain is MRSA or methicillin-sensitive (MSAA) which promotes targeted therapy.

The new MRSA/SA rapid test on Vivalytic by Bosch Healthcare Solutions GmbH (Waiblingen, Germany), a point of care platform brought to the market by Randox Laboratories (Crumlin, UK), delivers reliable results in under an hour directly at the point of care and is therefore, particularly suitable for use in accident and emergency units. Since the result of diagnostics with cultures is only available after one to three days, this PCR test for the point of care is ideal as an additional tool when speed is of the essence.

The quick and reliable diagnosis of whether the bacteria strain is MSSA or MRSA-resistant is also important in emergency situations. Waiting times for operations can, on the one hand, be reduced, while on the other enabling a decision on effective antibiotic treatment on this basis. This ability contributes to preventing contamination, breaking the chain of infection, and avoiding other resistances, which can, in turn, positively impact the treatment procedure and costs. Last but not least, unnecessary isolation measures, which are not only complex and expensive, but also put patients under even more pressure, can be avoided.

The advantages of PCR rapid tests administered with the aid of Bosch’s Vivalytic platform lie not only in the quick analysis time, but also in the ease of handling The Vivalytic system is a fully automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy-to-use cartridge contains all necessary reagents, is fully-sealed to minimize risk and can be conveniently stored at room temperature. The Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection. It follows an easy four step process from sample entry to results and with the gold standard PCR testing. With most up to date technology, the Vivalytic has wireless connectivity, with no peripherals required, making a unique space saving and hygienic solution. Handling and utilization are simple and medical professionals require only minimal training.

Related Links:
Randox Laboratories 
Bosch Healthcare Solutions GmbH 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.